The IgH.ETμ mouse model shows that BTK expression is a prerequisite for CLL development (32) whereas the TCL1 mouse model showed that mice with ablation of BTK significantly delayed CLL development but still developed leukemia at rates similar to wild type TCL1 mice treated with ibrutinib (33–35). The gene discussed is BTK; the disease is leukemia.